#	Pagina
attuale pagina	/open-h2020/projects/217072/results.html

Report

Teaser, summary, work performed and final results

Periodic Reporting for period 1 - iMOTED (iMOTED Platform Built to improve Clinical Trial outcomes)

Teaser

Summary

Biodatup promotes clinical trials (CT), using innovative technology to provide optimal results that match the needs of this demanding sector. iMOTED platform is a powerful and flexible Clinical Management System (CTMS) created to revolutionize the management of CTs. This platform combines the latest advances in engineering in medical information management, with the most innovative techniques of data analysis in health, such as modelling and big data among others.
Thanks to the development of IT tools, iMOTED can collect, integrate and validate clinical data from multicenter CT. The platform operates with real-time (RT) alarms to facilitate decision making, in case of unexpected results, allowing clinicians to make a quick and correct decision (e.g. human error, drugs interactions/toxicities).
iMOTED PHASE 1 OBJECTIVES
Task 1: Technical feasibility analysis.
Task 2: Commercial feasibility & Market study.
Task 3: Financial feasibility & Business Plan development.

Work performed

TECHNICAL FEASIBILITY STUDY: We defined a 2-year work plan and methodology, including a technological roadmap for iMOTED evolution based on customer and professionalsÂ´ feedbacks to achieve full technological readiness.
COMMERCIAL FEASIBILITY STUDY: A detailed market analysis (value, forecast, segments, drivers, etc.) performed during iMOTED FS allowed us validating our market hypothesis and the market opportunity for our technology. We also defined the best go-to-market plan considering the features of our potential clients.
FINANCIAL FEASIBILITY STUDY: FS has also allowed us analyzing the funding requirements to bring iMOTED to the market and we also elaborate financial projections to determine the profitability of the project in different scenarios.

Final results

iMOTED is a versatile CTMS intends to replace conventional CTMS. Its unique value proposition will allow the sponsors and researches to take early decisions, improving CT results and saving costs and time, based on RT analysis, pharmacological modeling, predictive tools as well as RT patientsÂ´ feedback from the beginning of the CT. All these characteristics mean a step forward, to move closer CTs to personalized medicine since our platform will allow a better definition of the drug effects and of CT results in different population groups and individuals.